Health ❯ Healthcare ❯ Clinical Trials

Phase 2 Trials

Dostarlimab Vaccine Efficacy eNRGy Trial Weight Loss Studies Study Results Silevertinib Trials Clinical Study Results WILLOW Trial AstraZeneca NOBILITY Trial

Lakewood-Amedex Says Nu-3 Did Not Induce Resistance in Lab Tests as Stock Soars

Preclinical data point to a high resistance barrier for a membrane-disrupting antibiotic pending clinical trials or funding decisions.

Spero Licenses Innovent’s Anti‑CD40L Antibody Outside Greater China in Up to $1.1 Billion Deal

AstraZeneca’s Oral GLP‑1 Elecoglipron Delivers Strong Phase 2 Weight and Blood‑Sugar Results

Roche Stops Phase 3 for Acmopatide After Positive Phase 2 in Type 1 Diabetes

Personalized mRNA Vaccine Halves Five‑Year Melanoma Recurrence Risk

Lilly Secures Global Rights to Hanmi’s Sonefpeglutide

FDA Accepts ImmunityBio Filing to Expand ANKTIVA Use in Bladder Cancer

Lifeward Completes Oratech Deal and Maps Back‑Half 2026 Recovery After Q1 Setbacks

FDA Clears All-Oral Decitabine/Cedazuridine Plus Venetoclax for Older AML Patients

Personalized mRNA Vaccine Shows Durable Survival Signal in Early Pancreatic Cancer

Cadonilimab Plus Chemo Delivers Strong Phase 2 Signal in Frontline Endometrial Cancer

EMA Panel Backs Conditional EU Approval for Ojemda in Pediatric Low-Grade Glioma

Roche’s CT-388 Shows Up to 22.5% Placebo-Adjusted Weight Loss in Phase 2 as Phase 3 Nears

Moderna–Merck Personalized Melanoma Vaccine Sustains 5-Year Benefit, Cutting Recurrence Risk by 49%

Amgen Reports Year-Long Weight-Loss Maintenance With Monthly or Quarterly MariTide Dosing

Phase II Trial Finds 24 Gy Preoperative Radiation With Pembrolizumab Boosts T‑Cell Infiltration in HR+/HER2− Breast Cancer

Structure Therapeutics' Oral GLP-1 Posts Up to 15% Placebo-Adjusted Weight Loss as Company Prepares Phase 3

KOMET-007 Shows 600 mg Ziftomenib Plus Venetoclax/Azacitidine Achieves Deep Remissions in NPM1‑Mutated AML

FDA Approves Breyanzi for Marginal Zone Lymphoma After Two or More Therapies

Silevertinib Delivers 60% Response and Strong CNS Activity in First-Line NSCLC With Non-Classical EGFR Mutations